A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020

Authors :: Schuster, Jennifer E
Halasa, Natasha B
Nakamura, Mari
Levy, Emily R
Fitzgerald, Julie C
Young, Cameron C
Newhams, Margaret M
Bourgeois, Florence
Staat, Mary A
Hobbs, Charlotte V
Dapul, Heda
Feldstein, Leora R
Jackson, Ashley M
Mack, Elizabeth H
Walker, Tracie C
Maddux, Aline B
Spinella, Philip C
Loftis, Laura L
Kong, Michele
Rowan, Courtney M
Bembea, Melania M
McLaughlin, Gwenn E
Hall, Mark W
Babbitt, Christopher J
Maamari, Mia
Zinter, Matt S
Cvijanovich, Natalie Z
Michelson, Kelly N
Gertz, Shira J
Carroll, Christopher L
Thomas, Neal J
Giuliano, John S
Singh, Aalok R
Hymes, Saul R
Schwarz, Adam J
McGuire, John K
Nofziger, Ryan A
Flori, Heidi R
Clouser, Katharine N
Wellnitz, Kari
Cullimore, Melissa L
Hume, Janet R
Patel, Manish
Randolph, Adrienne G
Source :: Journal of the Pediatric Infectious Diseases Society; May 2022, Vol. 11 Issue: 5 p191-198, 8p
Publication Year :: 2022
Abstract: No therapies for acute coronavirus disease 2019 (COVID-19) have been tested in children to establish effectiveness. Despite this, across 48 hospitals, 235/424 children (55%) admitted to the intensive care or step-down unit with COVID-19 received directed therapies. Systemic steroids and remdesivir were most commonly administered, with use rising from March 2020 to December 2020.

Full Text Access

Tools